Skip to main content
Top
Published in: Abdominal Radiology 4/2013

01-08-2013

Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma

Authors: Hyun Jeong Park, Young Kon Kim, Min Jung Park, Won Jae Lee

Published in: Abdominal Radiology | Issue 4/2013

Login to get access

Abstract

Purpose

To determine the differential MRI features of small mass-forming intrahepatic cholangiocarcinoma (ICC) from hepatocellular carcinoma (HCC).

Methods

Sixty-four patients with pathologically proven small ICCs (n = 32) and HCCs (n = 32) (≤3.0 cm in diameter) who had undergone preoperative gadoxetic acid-enhanced MRI and DWI were enrolled in this study. Images were analyzed for the shape of the lesions, the presence of biliary dilatation, hyperenhancement (>50 % of the tumor volume) or rim enhancement on the arterial phase, capsular enhancement, and the presence of target appearance (a central enhancement with hypointense rim) on the hepatobiliary phase and on DWI (a central hypointense area with a peripheral hyperintense rim). Statistical significance of these findings was determined by the χ2 or Fisher’s exact test. Multivariate analysis was performed to identify independent imaging findings that allow differentiation of the two diseases.

Results

Univariate analysis revealed that the following significant parameters favor ICC over HCC: lobulating shape, rim enhancement on arterial phase, target appearance on the hepatobiliary phase, and DWI (P < 0.05). Multivariate logistic regression analysis revealed that only target appearance on the DWI was a significant and independent variable predictive of ICC, as 24 ICCs (75.0 %) and one HCC (3.1 %) showed this feature (P = 0.0003).

Conclusion

A target appearance on the DWI was the most reliable imaging feature for distinguishing small mass-forming ICC from small HCC.
Literature
1.
go back to reference Kham SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366:1303–1314CrossRef Kham SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366:1303–1314CrossRef
2.
go back to reference Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353–1357PubMedCrossRef Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353–1357PubMedCrossRef
3.
4.
go back to reference Lim JH (2003) Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol 181:819–827PubMedCrossRef Lim JH (2003) Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol 181:819–827PubMedCrossRef
5.
go back to reference Choi BI, Han JK, Shin YM, Baek SY, Han MC (1995) Peripheral cholangiocarcinoma: comparison of MRI with CT. Abdom Imaging 20:357–360PubMedCrossRef Choi BI, Han JK, Shin YM, Baek SY, Han MC (1995) Peripheral cholangiocarcinoma: comparison of MRI with CT. Abdom Imaging 20:357–360PubMedCrossRef
6.
go back to reference Fan ZM, Yamashita Y, Harada M, et al. (1993) Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging. AJR Am J Roentgenol 161:313–317PubMedCrossRef Fan ZM, Yamashita Y, Harada M, et al. (1993) Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging. AJR Am J Roentgenol 161:313–317PubMedCrossRef
7.
go back to reference Hamrick-Turner J, Abbitt PL, Ros PR (1992) Intrahepatic cholangiocarcinoma: MR appearance. AJR Am J Roentgenol 158:77–79PubMedCrossRef Hamrick-Turner J, Abbitt PL, Ros PR (1992) Intrahepatic cholangiocarcinoma: MR appearance. AJR Am J Roentgenol 158:77–79PubMedCrossRef
8.
go back to reference Maetani Y, Itoh K, Watanabe C, et al. (2001) MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 176:1499–1507PubMedCrossRef Maetani Y, Itoh K, Watanabe C, et al. (2001) MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 176:1499–1507PubMedCrossRef
9.
go back to reference Tani K, Kubota Y, Yamaguchi T, et al. (1991) MR imaging of peripheral cholangiocarcinoma. J Comput Assist Tomogr 15:975–978PubMedCrossRef Tani K, Kubota Y, Yamaguchi T, et al. (1991) MR imaging of peripheral cholangiocarcinoma. J Comput Assist Tomogr 15:975–978PubMedCrossRef
10.
go back to reference Vilgrain V, Van Beers BE, Flejou JF, et al. (1997) Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr 21:59–65PubMedCrossRef Vilgrain V, Van Beers BE, Flejou JF, et al. (1997) Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr 21:59–65PubMedCrossRef
11.
go back to reference Rimola J, Forner A, Reig M, et al. (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50:791–798PubMedCrossRef Rimola J, Forner A, Reig M, et al. (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50:791–798PubMedCrossRef
12.
go back to reference Vilana R, Forner A, Bianchi L, et al. (2010) Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51:2020–2029PubMedCrossRef Vilana R, Forner A, Bianchi L, et al. (2010) Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51:2020–2029PubMedCrossRef
13.
go back to reference Kim SA, Lee JM, Lee KB, et al. (2011) Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern-correlation with clinicopathologic findings. Radiology 260:148–157PubMedCrossRef Kim SA, Lee JM, Lee KB, et al. (2011) Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern-correlation with clinicopathologic findings. Radiology 260:148–157PubMedCrossRef
14.
go back to reference Kim SJ, Lee JM, Han JK, et al. (2007) Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. AJR Am J Roentgenol 189:1428–1434PubMedCrossRef Kim SJ, Lee JM, Han JK, et al. (2007) Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. AJR Am J Roentgenol 189:1428–1434PubMedCrossRef
15.
go back to reference El-Serag HB, Engels EA, Landgren O, et al. (2009) Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology 49:116–123PubMedCrossRef El-Serag HB, Engels EA, Landgren O, et al. (2009) Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology 49:116–123PubMedCrossRef
16.
go back to reference Bruix J, Sherman M, American Association for the Study of Liver Disease (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1021PubMedCrossRef Bruix J, Sherman M, American Association for the Study of Liver Disease (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1021PubMedCrossRef
17.
go back to reference Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef
18.
go back to reference Kim YK, Kim CS, Han YM, Park G (2010) Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol 45:740–746PubMedCrossRef Kim YK, Kim CS, Han YM, Park G (2010) Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol 45:740–746PubMedCrossRef
19.
go back to reference Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681PubMedCrossRef Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681PubMedCrossRef
20.
go back to reference Kim YK, Kim CS, Han YM, et al. (2009) Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr 33:844–850PubMedCrossRef Kim YK, Kim CS, Han YM, et al. (2009) Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr 33:844–850PubMedCrossRef
21.
22.
go back to reference Kim YK, Lee MW, Lee WJ, et al. (2012) Diagnostic accuracy and sensitivity of diffusion-weighted and gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (≤1.5 cm in diameter). Invest Radiol 47:159–166PubMed Kim YK, Lee MW, Lee WJ, et al. (2012) Diagnostic accuracy and sensitivity of diffusion-weighted and gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (≤1.5 cm in diameter). Invest Radiol 47:159–166PubMed
23.
go back to reference Bolondi L, Gaiani S, Celli N, et al. (2005) Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42:27–34PubMedCrossRef Bolondi L, Gaiani S, Celli N, et al. (2005) Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42:27–34PubMedCrossRef
24.
go back to reference Holland AE, Hecht EM, Hahn WY, et al. (2005) Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology 237:938–944PubMedCrossRef Holland AE, Hecht EM, Hahn WY, et al. (2005) Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology 237:938–944PubMedCrossRef
25.
go back to reference Kim YK, Lee JM, Kim CS (2004) Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 14:5–13PubMedCrossRef Kim YK, Lee JM, Kim CS (2004) Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 14:5–13PubMedCrossRef
26.
go back to reference Tamada T, Ito K, Sone T, et al. (2009) Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging 29:636–640PubMedCrossRef Tamada T, Ito K, Sone T, et al. (2009) Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging 29:636–640PubMedCrossRef
27.
go back to reference Gabata T, Matsui O, Kadoya M, et al. (1998) Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging 23:309–313PubMedCrossRef Gabata T, Matsui O, Kadoya M, et al. (1998) Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging 23:309–313PubMedCrossRef
28.
go back to reference Kim YK, Han YM, Kim CS (2009) Comparison of diffuse hepatocellular carcinoma and intrahepatic cholangiocarcinoma using sequentially acquired gadolinium-enhanced and Resovist-enhanced MRI. Eur J Radiol 70:94–100PubMedCrossRef Kim YK, Han YM, Kim CS (2009) Comparison of diffuse hepatocellular carcinoma and intrahepatic cholangiocarcinoma using sequentially acquired gadolinium-enhanced and Resovist-enhanced MRI. Eur J Radiol 70:94–100PubMedCrossRef
Metadata
Title
Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma
Authors
Hyun Jeong Park
Young Kon Kim
Min Jung Park
Won Jae Lee
Publication date
01-08-2013
Publisher
Springer US
Published in
Abdominal Radiology / Issue 4/2013
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-012-9943-x

Other articles of this Issue 4/2013

Abdominal Radiology 4/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.